AI-Human Collaboration in Liver Tumor Diagnosis with DCE-CT
This study aims to evaluate how artificial intelligence can assist doctors in diagnosing liver tumors using dynamic contrast-enhanced computed tomography in patients.
AI-human collaboration for CE-CTs diagnosis
Adenocarcinoma+13
+ Carcinoma
+ Cysts
Diagnostic Study
Summary
Study start date: September 1, 2025
Actual date on which the first participant was enrolled.This clinical study explores how artificial intelligence (AI) can work together with human doctors to improve the diagnosis of liver tumors using a special type of imaging called dynamic contrast-enhanced computed tomography (DCE-CT). AI has shown great potential in analyzing medical images, sometimes even matching or surpassing the skills of experienced doctors. However, challenges remain in applying these AI tools in real-world settings due to variability in patient populations and imaging conditions. By investigating this collaboration, the study aims to enhance diagnostic accuracy and create a more reliable framework for diagnosing liver tumors. In the study, radiologists and an AI system will simultaneously analyze the same DCE-CT images. Radiologists will follow their usual procedures, while the AI system provides its analysis independently. When their assessments differ, a panel of experts will review the cases to reach a final decision. This process helps to identify how human expertise and AI can complement each other, improving overall diagnostic performance. By including a wide range of clinical cases, the study seeks to ensure the AI’s effectiveness across different scenarios, ultimately aiming to improve the integration of AI into clinical practice.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.10333 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: 1. Age range 18 years and above 2. Underwent dynamic contrast-enhanced abdominal CT examination with liver coverage 3. Imaging must include at least three required phases: non-contrast, arterial phase, and venous phase; an delayed phase is optional 4. Complete imaging data that meet AI system analysis requirements. Exclusion Criteria: 1. History of recent upper-abdominal surgery (within 30 days) or major hepatobiliary-pancreatic surgery affecting liver evaluation (e.g., liver transplantation or Whipple procedure); patients with prior simple cholecystectomy or single-lesion interventional procedures are not excluded 2. History of recent hepatic trauma (within 30 days) 3. Poor image quality or severe noise artifacts (e.g., metal or motion artifacts) 4. Missing required imaging phases (required at least non-contrast, arterial, and venous phases) or inadequate scan range (e.g., lower-abdomen CT such as pelvic or rectal scans not covering the liver)
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Shengjing Hospital of China Medical University
Shenyang, ChinaOpen Shengjing Hospital of China Medical University in Google Maps